(Q33746632)

29 July 2017

1 reference

title

High-density lipoprotein subclasses and apolipoprotein A-I. (English)

1 reference

29 July 2017

Duriez P

1

1 reference

29 July 2017

Fruchart JC

series ordinal

2

1 reference

29 July 2017

publication date

1 August 1999

1 reference

29 July 2017

1 reference

29 July 2017

volume

286

1 reference

29 July 2017

issue

1-2

1 reference

29 July 2017

page(s)

97-114

1 reference

The American College of Physicians guidelines for screening blood cholesterol levels: a commentary

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2899%2900096-0

Inhibition of Atherosclerosis Development in Cholesterol-Fed Human Apolipoprotein A-I–Transgenic Rabbits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2899%2900096-0

Isolation and partial characterization of lipoprotein A-II (LP-A-II) particles of human plasma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2899%2900096-0

Differential role of apolipoprotein AI-containing particles in cholesterol efflux from adipose cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2899%2900096-0

Purification of an apolipoprotein A binding protein from mouse adipose cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2899%2900096-0

Role of apolipoproteins in cholesterol efflux from macrophages to lipid microemulsion: proposal of a putative model for the pre-beta high-density lipoprotein pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2899%2900096-0

Cholesterol efflux from adipose cells is coupled to diacylglycerol production and protein kinase C activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2899%2900096-0

Modulation of cholesterol efflux from Fu5AH hepatoma cells by the apolipoprotein content of high density lipoprotein particles. Particles containing various proportions of apolipoproteins A-I and A-II

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2899%2900096-0

Human apolipoproteins A-I and A-II in cell cholesterol efflux: studies with transgenic mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2899%2900096-0

Plasma concentrations of apolipoprotein A-I containing particles in normolipidaemic young men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2899%2900096-0

Production of small high-density lipoprotein particles after stimulation of in vivo lipolysis in hypertriglyceridemic individuals: studies before and after triglyceride-lowering therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2899%2900096-0

High-density lipoprotein particles in octogenarians

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2899%2900096-0

Apolipoprotein A-I containing lipoproteins in coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2899%2900096-0

Plasma apolipoprotein A-I, A-II, B, E and C-III containing particles in men with premature coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2899%2900096-0

Parental history of early myocardial infarction is associated with decreased levels of lipoparticle AI in adolescents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2899%2900096-0

Lipoprotein composition changes induced by fenofibrate in dysbetalipoproteinemia type III

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2899%2900096-0

Evaluation of apolipoprotein A-I containing particles in chronic renal failure patients undergoing hemodialysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2899%2900096-0

Lowering of HDL2-cholesterol and lipoprotein A-I particle levels by increasing the ratio of polyunsaturated to saturated fatty acids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2899%2900096-0

Reduced progression of atherosclerosis in apolipoprotein E-deficient mice following consumption of red wine, or its polyphenols quercetin or catechin, is associated with reduced susceptibility of LDL to oxidation and aggregation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2899%2900096-0

Consumption of red wine polyphenols reduces the susceptibility of low-density lipoproteins to oxidation in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2899%2900096-0

Proanthocyanidin-rich extract from grape seeds attenuates the development of aortic atherosclerosis in cholesterol-fed rabbits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2899%2900096-0

A multicenter comparison of the effects of simvastatin and fenofibrate therapy in severe primary hypercholesterolemia, with particular emphasis on lipoproteins defined by their apolipoprotein composition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2899%2900096-0

Effect of pravastatin, an HMG CoA reductase inhibitor, and cholestyramine, a bile acid sequestrant, on lipoprotein particles defined by their apolipoprotein composition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2899%2900096-0

Double-Blind Comparison of Apolipoprotein and Lipoprotein Particle Lowering Effects of Atorvastatin and Pravastatin Monotherapy in Patients With Primary Hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2899%2900096-0

Comparison of the effect of fluvastatin, an hydroxymethyl glutaryl coenzyme A reductase inhibitor, and cholestyramine, a bile acid sequestrant, on lipoprotein particles defined by apolipoprotein composition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2899%2900096-0

Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2899%2900096-0

High level expression of human apolipoprotein A-I in transgenic rats raises total serum high density lipoprotein cholesterol and lowers rat apolipoprotein A-I

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2899%2900096-0

Transgenic Rabbits Expressing Human Apolipoprotein A-I in the Liver

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2899%2900096-0

Expression of human apolipoprotein A-I in transgenic mice results in reduced plasma levels of murine apolipoprotein A-I and the appearance of two new high density lipoprotein size subclasses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2899%2900096-0

Marked reduction of high density lipoprotein cholesterol in mice genetically modified to lack apolipoprotein A-I

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2899%2900096-0

Expression of the human apolipoprotein A-I gene in transgenic mice alters high density lipoprotein (HDL) particle size distribution and diminishes selective uptake of HDL cholesteryl esters

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2899%2900096-0

Protein composition determines the anti-atherogenic properties of HDL in transgenic mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2899%2900096-0

Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2899%2900096-0

Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2899%2900096-0

HDL deficiency in genetically engineered mice requires elevated LDL to accelerate atherogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2899%2900096-0

Elevated triglycerides and low HDL cholesterol in transgenic mice expressing human apolipoprotein A-IMilano

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2899%2900096-0

Atherosclerosis in transgenic mice overexpressing apolipoprotein A-II.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2899%2900096-0

Contrasting in vivo effects of murine and human apolipoprotein A-II. Role of monomer versus dimer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2899%2900096-0

Overexpression of apolipoprotein AII in transgenic mice converts high density lipoproteins to proinflammatory particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2899%2900096-0

Protection against atherogenesis in mice mediated by human apolipoprotein A-IV

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2899%2900096-0

Reduced aortic lesions and elevated high density lipoprotein levels in transgenic mice overexpressing mouse apolipoprotein A-IV.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2899%2900096-0

New recommendations for the diagnosis and treatment of plasma lipid abnormalities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2899%2900096-0

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0009-8981(99)00096-0

1 reference

29 July 2017

1 reference